Introduction

Focal brachytherapy (FBT) emerged as a reasonable option to treat patients with favorable prostate cancer (PCa). The aim of this study is to evaluate the early functional and oncological outcomes of FBT in the treatment of localized PCa._x000D_

Methods

A retrospective review was performed at our prospective collected PCa database, searching for patients treated with FBT between 2010 and 2015. A cohort of 100 individuals treated with whole gland brachytherapy (WBT) in the same period was assessed in order to perform a comparison. IPSS, ICS and IIEF5 questionnaires were used to evaluate urinary symptoms, continence and sexual function, respectively, at 6, 12 and 24 months. All patients in the FBT group had a control prostate biopsy; PCa recurrence was defined as positive biopsy at the same treatment site. In the WBT group, PCa recurrence was defined by PSA increase > nadir + 2.

Results

Forty patients were included in the FBT group with complete oncological follow-up. Twenty-seven patients had completed questionnaires with 24 months of follow-up (included in the functional assessment). Initial presentation and treatment characteristics are exhibited on table 1. Median follow-up for FBT and WBT groups were 34 months (range: 10-68 months) and 24 months (range: 24-36 months), respectively. There was no difference in recurrence rates between-groups (FBT 7.5% vs. WBT 3%, p = 0.35) (fig. 1). WBT group had significant worsening of urinary symptoms when compared to FBT group at 6 months (p = 0.003), but not with 12 and 24 months. Urinary continence and sexual function was similar between-groups.

Conclusions

FBT has satisfactory oncological outcomes and less urinary symptoms at early follow-up when compared to WBT. Urinary continence and sexual functional is the same as WBT.

Funding

None